Table 2.
Results of subgroup analysis for ORR and DCR
| Subgroups | Studies (n) | Weighted estimates (95% CI) | Heterogeneity test |
|---|---|---|---|
| ORR | |||
| Dosage of gemcitabine | |||
| 1,000 mg/m2 | 17 | 13.3 (10.7–16.4) | I2=32.6%, P=0.013 |
| >1,000 mg/m2 | 3 | 21.6 (12.8–34.0) | I2=34.2%, P=0.111 |
| Dosage of erlotinib | |||
| 100 mg/d | 14 | 15.3 (12.1–19.2) | I2=35.8%, P=0.006 |
| 100–150 mg/d | 3 | 8.2 (5.6–11.8) | I2=0%, P=0.396 |
| 150 mg/d | 3 | 15.1 (7.7–27.6) | I2=30.6%, P=0.143 |
| Sample size | |||
| Large studies | 3 | 9.0 (7.1–11.3) | I2=0%, P=0.363 |
| Small studies | 17 | 16.8 (13.8–20.2) | I2=18.8%, P=0.157 |
| DCR | |||
| Dosage of gemcitabine | |||
| 1,000 mg/m2 | 15 | 55.2 (52.2–58.2) | I2=8.7%, P=0.257 |
| >1,000 mg/m2 | 4 | 53.7 (37.8–68.9) | I2=41.3%, P=0.017 |
| Dosage of erlotinib | |||
| 100 mg/d | 13 | 54.2 (49.8–58.6) | I2=28.8%, P=0.060 |
| 100–150 mg/d | 3 | 59.8 (48.0–70.5) | I2=23.1%, P=0.193 |
| 150 mg/d | 3 | 53.4 (43.7–62.9) | I2=0%, P=0.294 |
| Sample size | |||
| Large studies | 3 | 57.0 (53.4–60.5) | I2=0%, P=0.340 |
| Small studies | 7 | 53.9 (49.0–58.8) | I2=26.6%, P=0.069 |
Abbreviations: ORR, objective response rate; DCR, disease control rate; CI, confidence interval; d, day.